Artículo
Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity
Autor/es | Borrego Écija, Sergi
Pérez Millan, Agnès Antonell, Anna Fort Aznar, Laura Kaya Tilki, Elif León Halcón, Alberto Vitorica Ferrández, Francisco Javier Venero Recio, José Luis Boza Serrano, Antonio |
Departamento | Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular |
Fecha de publicación | 2023-11 |
Fecha de depósito | 2024-03-07 |
Publicado en |
|
Resumen | INTRODUCTION
Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. ... INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential. METHODS We examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples of patients with FTD and controls. Multiple linear regressions between Gal-3 levels and other FTD markers were explored. RESULTS Gal-3 levels were increased significantly in patients with FTD, mainly across brain tissue and CSF, compared to controls. Remarkably, Gal-3 levels were higher in cases with tau pathology than TAR-DNA Binding Protein 43 (TDP-43) pathology. Only MAPT mutation carriers displayed increased Gal-3 levels in CSF samples, which correlated with total tau and 14-3-3. DISCUSSION Our findings underscore the potential of Gal-3 as a diagnostic marker for FTD, particularly in MAPT cases, and highlights the relation of Gal-3 with neuronal injury markers. |
Agencias financiadoras | Instituto de Salud Carlos III Generalitat de Catalunya Ministerio de Ciencia e Innovación (MICIN). España European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) |
Identificador del proyecto | PI20/0448
PI19/00449 PI18/01556 PI21/00914 SGR2021- 01126 PID2021-124096OB-I00 |
Cita | Borrego Écija, S., Pérez Millan, A., Antonell, A., Fort Aznar, L., Kaya Tilki, E., León Halcón, A.,...,Boza Serrano, A. (2023). Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity. Alzheimer's & Dementia, 2023, 1-12. https://doi.org/10.1002/alz.13536. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Alzheimer s Dementia - 2023 - ... | 740.4Kb | [PDF] | Ver/ | |